Jacalyn M Rosenblatt MD

Assistant Professor, Medicine-Beth Israel Deaconess Medical Center, Harvard Medical School

330 Brookline Avenue, Ks-121Beth Israel Deaconess HospitalBoston, MA 02215
Phone+1 617-667-9920

Dr. Rosenblatt is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rosenblatt's full profile Already have an account?

Education & Training

McGill University Faculty of MedicineClass of 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2003 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification Quality Data Center, Massachusetts eHealth Collaborative (MAeHC), 2012, 2014-2017

Clinical Trials

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
COMPLETED
PHASE2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
COMPLETED
PHASE2, PHASE3
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
TERMINATED
PHASE1

Publications & Presentations

PubMed

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Omar Nadeem, Michelle P Aranha, Robert A Redd, Michael Koontz, Jeffrey V Matous
Nature Communications. 2026-04-08
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Melissa Alsina, Nina Shah, Sundar Jagannath, Jonathan L Kaufman, David Siegel
Cancer Immunology Research. 2026-04-02
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.
William C Pilcher, Lijun Yao, Edgar Gonzalez-Kozlova, Yered Pita-Juarez, Dimitra Karagkouni
Nature Cancer. 2026-01-01

Abstracts/Posters

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine
Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy
Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

BIDMC Marks International Day of Women and Girls in ScienceFebruary 11th, 2020
Emerging Therapies for Multiple MyelomaMay 30th, 2019
Taking a New Shot at Tumor VaccinesMarch 6th, 2019

Grant Support

Personalized Adoptive T-cell Therapy for AMLBETH ISRAEL DEACONESS MEDICAL CENTER2021–2026
Personalized Adoptive T-cell Therapy for AMLBETH ISRAEL DEACONESS MEDICAL CENTER2021–2026
Personalized Adoptive T-cell Therapy for AMLBETH ISRAEL DEACONESS MEDICAL CENTER2021–2026